Korea Research Institute of Chemical Technology

Katholieke Universiteit Leuven

Katholieke Universiteit Leuven, Ku Leuven R&d

K.u. Leuven Research & Development

Gilead Sciences, Inc.

Other

Novartis Ag

Aratana Therapeutics, Inc.

Centre National De La Recherche Scientifique

Consiglio Nazionale Delle Ricerche

Université´ D'aix-Marseille

Aix-Marseille Université

.kemin Foods, L.c.

Kemin Pharma B.v.b.a.

Université Francois Rabelais De Tours

Johan Neyts

Hae Soo Kim

Soo Bong Han

Young Sik Jung

Hendrik Jan Thibaut

Jin Soo Shin

Chong-Kyo Lee

Gerhard Pürstinger

Choung U Kim

David A Oare

Erik De Clercq

Kai Dallmeier

Stefaan Wera

Pil Ho Kim

Erwin Blomsma

Maryline Roe

Nesya Goris

Ainola Billiet

Joeri Auwerx

Daniel J Poon

Jan Balzarini

Keith Bruce Pfister

Steven S Bondy

Vahid Zia

Eric Dowdy

Benedikt J Sas

Chong Ock Lee

Jan Vandenkerckhove

Eric Peys

Johan Van Hemel

Young-Sik Jung

Johan Van Der Eycken

Suzanne Kaptein

Bart Ruttens

Marcela Krecmerova

Jean-Louis Romette

Bruno Canard

Gerhard Puerstinger

Martino Bolognesi

Antonin Holy

Veerle Debeurme

Pascal Puig

Chonsaeng Kim

Prashant Chakrasali

Niraj Mishra

Yashwardhan R Malpani

Ihl Young Choi

Chong Kgo Lee

Hee Chun Jeong

Yashwardhan Radhamohan Malpani

Eloise Mastrangelo

Mario Milani De Mayo De Mari

Jean-Michel Chezal

Alain Gueiffier

Vincent Gaumet

Robbert Boudewijns

Sang-Ho Lee

Bishyajit Kumar Biswas

Lorena Sanchez

Karine Barral

Lieve Naesens

Robert Snoeck

Graciela Andrei

Alois Piskala

Jean-Claude Teulade

Olivier Chavignon

Jan Paeshuyse

Boris Pastorino

Eric De Clercq

Dieudonné Buh Kum

Karine Alvarez

Phil Ho Kim

Michael Alexander Schmid

Marcela Krecmerová

Eric Davis Dowdy

Aino Billiet

Benedikt Sas

The invention provides compounds of Formula (I):

Antiviral 1,3-di-oxo-indene compounds

This disclosure provides compounds of Formula (I)

The invention describes chimeric Flavivirus constructs comprising lyssavirus G proteins in the E/NS1 intergenic region.

Chimeric flavivirus lyssavirus vaccines

The present invention relates to an eye-drop composition comprising 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one, and the use thereof for the diagnosis and treatment of herpetic eye infections in companion animals.

Eye drop composition

The invention relates to polynucleotides comprising the sequence of a flavivirus preceded by a sequence encoding an N terminal part of a flavivirus Capsid protein, an immunogenic protein, or a part thereof comprising a an immunogenic peptide, and a 2A cleaving peptide, and to the virus encoded by such sequences. The invention further relates to the use of such polynucleotides and viruses as vaccines.

Live-attenuated flaviruses with heterologous antigens

The present invention relates to chimeric yellow fever&#x2014;Zika strains and attenuated versions thereof, wherein the nucleotide sequence encoding the signal sequence and prME protein of said yellow virus is replaced by a nucleotide sequence encoding the signal sequence and the prME protein of a Zika virus.

Chimeric yellow fever ZIKA virus strain

The present invention relates to a novel compound, to a pharmaceutically acceptable salt or optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition for the prevention or treatment of viral diseases containing same as an active ingredient. The novel compound according to the present invention not only has low cytotoxicity but also has excellent antiviral activity against picornavirus such as coxsackievirus, enterovirus, echovirus, poliovirus and rhinovirus, and thus can be effectively used as a pharmaceutical composition for the prevention or treatment of viral diseases such as infantile paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myitis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinus infection, or otitis media.

Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing the same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient

Disclosed are novel indanone derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The indanone derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases

Disclosed are 1,3-Dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-Dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

1,3-Di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient

Disclosed are indanone derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The indanone derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

Disclosed are 1,3-Dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-Dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, flu, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

1,3-di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient

This invention relates to a purine or pyrimidine phosphonate compound of formula (I) or pharmaceutically acceptable salt thereof; wherein B, X, and R-Rare as defined in classes and subclasses herein. These compounds may be used as antiviral precursors. The invention also relates to therapeutic compositions of these compounds and their use for the preparation of a medication for testing and/or preventing a viral infection in a patient. The invention also provides methods for making these compounds. In particular, the invention provides an H-phosphinate precursor intermediate of formula (II) wherein B is a purine or pyrimidine base as defined herein and Ris selected from the group comprising a hydrogen atom, and a methyl, ethyl, hydroxymethyl, hydroxyethyl and Chaloalkyl group.

Nucleotide analogues as precursor molecules for antivirals

Growing community of inventors

Kessel-lo, Belgium

Johan Neyts